Ependymoma Pipeline Review, H2 2018: Therapeutic Development & Assessment, Companies, Drug Profiles & Dormant Projects - ResearchAndMarkets.com

October 9, 2018

DUBLIN--(BUSINESS WIRE)--Oct 9, 2018--The “Ependymoma - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Ependymoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ependymoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 9, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ependymoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Ependymoma - Overview Ependymoma - Therapeutics Development Ependymoma - Therapeutics Assessment Ependymoma - Companies Involved in Therapeutics Development Ependymoma - Drug Profiles Ependymoma - Dormant Projects Appendix

Companies Mentioned

Advantagene Inc AstraZeneca Plc Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Celgene Corp Eli Lilly and Co Kite Pharma Inc NewLink Genetics Corp Novartis AG Ono Pharmaceutical Co Ltd Pfizer Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4hnpvh/ependymoma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005930/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs ,Brain Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/09/2018 12:28 PM/DISC: 10/09/2018 12:28 PM


Update hourly